Short stature is a potential side-effect of BMT, brought This study included 30 patients given allogeneic BMT at about by the conditioning protocol and/or the compli-0.2 to 9 years, between 1982 and 1990, conditioned by cations of BMT. This study evaluates the effects of conchemotherapy alone (Table 1 ). The duration of follow-up ditioning by chemotherapy, and BMT complications on was 3.5 ± 0.2 (s.e.m) years (range 2-5.5 years). Fifteen of growth. Thirty children conditioned for BMT by them were severely growth retarded (heights р −2 s.d.) at chemotherapy alone (cyclophosphamide and busulfan)
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compared
1.7 ± 0.5 −1.8 ± 0.3 −1.7 ± 0.2 0.3 ± 0.1 0.7 ± 0.3 to 2 NS NS P Ͻ 0.001 NS P Ͻ 0.01 a 1 = cyclophosphamide; 2 = busulfan; 3 = etoposide; 4 = methotrexate; 5 = cyclosporine; 6 = antithymocyte globulin. b The normal limits for plasma IGFI in age-matched controls are 0.15-1.1 U/ml. c P Ͻ 0.01 and 0.04 as compared to time of BMT for height and IGFI, respectively. IGFI = insulin-like growth factor I; CID = congenital immunodeficiency; LAD = leukocyte adhesion deficiency.
Results height, BMI and plasma IGFI level patterns did not differ when patients were classified according to their initial disease. At the time of BMT, the two groups were comparable in terms of distribution of initial diseases, regimens of chemo-
The mean height was 0.5 ± 0.3 in group 1 (n = 8) and −1.6 ± 0.3 s.d. in group 2 (n = 11) 4 years after BMT. therapy, age, height, body-mass index (BMI, weight in kg/height in m 2 ) and plasma IGFI level (Table 1) . Two years after BMT, however, the height and plasma IGFI levels in group 1 were significantly higher than in group 2 and Discussion than the values at the time of BMT (Figure 1 ). After this time interval, only 10 group 2 patients had a height This study shows that conditioning by chemotherapy alone does not prevent the catch-up growth induced by BMT in р −2 s.d. The six group 1 patients reevaluated for their plasma IGFI after 2 years, had concentrations above the young children who are growth retarded because of their initial disease. The lack of catch-up growth appears to be normal limits. In group 1, the height increase after 2 years was significantly greater when patients were younger due to complications occurring after BMT. This suggests that impaired growth in previously reported patients given (P Ͻ 0.03) and smaller (P Ͻ 0.001) at BMT. It was not correlated with the increase in BMI. The BMI score non-body irradiation containing regimens was due to factors other than these regimens. increased from −0.4 ± 0.4 to 0.2 ± 0.4 (NS) in group 1, and from −1.3 ± 0.4 to 0 ± 0.4 (P Ͻ 0.01) in group 2. The
The effect of chemotherapy on growth has been previously analyzed in patients treated for acute lymphothe patients with chronic GVHD were not given glucocorticoid therapy, and their growth velocity was not disblastic leukemia by chemotherapy alone, or by chemotherapy plus cranial irradiation, and in patients conditioned tinguishable from that of those patients who were given glucocorticoid therapy. Bushhouse et al 10 showed that the for BMT by chemotherapy alone. It has been suggested that the more decreased growth rate in some patients treated for four patients with extensive chronic GVHD experienced greater growth suppression than those with no GVHD. leukemia, may be due to prolonged, 3 or more intensive 4 chemotherapy. The growth of patients given BMT was
In conclusion, this study shows that chemotherapy has no deleterious effect on growth. However, the majority of found to be affected by the chemotherapy in some reports 5, 6 but not in others. 7 Willi et al 5 found that the mean growth the patients were less than 2 years old at BMT. As busulfan has a higher clearance and a larger volume of distribution velocity in patients given BMT for advanced neuroblastoma was significantly lower than in those treated for leukein young children, 11 it may be less toxic. Thus, the present situation should be evaluated in older patients. mia or aplastic anemia. They concluded that the very intensive preparative regimens, including the doses of local radiotherapy and type and number of cytotoxic agents used for patients with neuroblastoma, had significantly negative Acknowledgements effects on growth. Wingard et al 6 used the same conditioning protocol as us, and found that cyclophosphamide plus We thank MC Perret for technical assistance, the NIDDK (Baltimore, MD, USA), for the gift of anti-IGFI immunoserum, busulfan had a striking effect on the growth rates of many M Lacroix for preparing the manuscript, and Dr O Parkes for of the children. This effect was comparable to that of cycloeditorial help. This work was supported by a grant from the phosphamide plus total body irradiation. Recently, Giorgi- 
